舒利迭联合顺尔宁治疗咳嗽变异型哮喘的疗效观察

Clinical observation on Seretide in combination with montelukast in treatment of cough variant asthma

目的观察咳嗽变异型哮喘(CVA)患者单用顺尔宁、舒利迭及二药联用的治疗效果。以评价舒利迭、顺尔宁在治疗CVA的应用价值。方法选择2010年10月至2011年11月在本院门诊就诊的60例CVA患者,随机分为三组。顺尔宁组10 mg每晚口服1次;舒利迭组50μg/250μg吸入,早、晚各1次,吸完漱口;联合治疗组吸入舒利迭50μg/250μg,早、晚各1次,顺尔宁10 mg每晚口服1次。结果临床表现变化:三组原有症状均有不同程度缓解。联合治疗组患者症状缓解、生存质量、疾病进展时间明显优于舒利迭组、顺尔宁组,舒利迭组优于顺尔宁组。结论舒利迭治疗CVA时,与顺尔宁联合应用,其可以减少激素吸入量而不影响治疗效果,并且因其服用方便、快速起效及不良反应少的优点可以提高患者的依从性。

Objective To compare the efficiency of seretide plus montelukast and seretide only and montelukast only on patients with cough variant asthma（CVA）.Methods General condition of the patients： 60 patients with definite diagnosed of CVA admitted into The Second Hospital of Shandong University from October 2010 to November 2011 were enrolled into our study,including 26 males and 34 females.Clinical treatment： Sixty patients with CVA were randomly divided into three groups treated with seretide plus montelukast and seretide only and montelukast.The pulmonary function and clinical symptom before and after treatment were observed in three groups.Results The symptom score in the group plus montelukast were significantly lower than that in the group seretide only（P ＆lt; 0.01）,and the group seretide only was significantly lower than that in the group montelukast only（P ＆lt; 0.01）.Conclusion The clinical improvement appears more rapidly in treatment by seretide plus montelukast than by seretide only,and more rapidly in treatment by seretide only than by montelukast only.